Get started
Author

Julien Taurelle

Observed institution: OSE Immunotherapeutics (France)
OpenAlex ID: A5028129441
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis
2024 · Lennart Lenk, Irène Baccelli, et al. · Blood · 20
PDF
Abstract 2957: CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by the IL7R-antagonist OSE-127 through macrophage-mediated antibody dependent phagocytosis
2023 · Irene Baccelli, Lennart Lenk, et al. · Cancer Research · 1
The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action
2022 · Lennart Lenk, Irène Baccelli, et al. · Blood · 1
Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040
2026 · Charles-Antoine Coupet, Charlène Trilleaud, et al. · The Journal of Immunology
Abstract 3412: Cis demasking cytokine technology improves therapeutic index of immunocytokine
2025 · Caroline Mary, Margaux Seite, et al. · Cancer Research
Abstract 4070: CIS-demasking cytokine linker technology allows a selective cytokine delivery to activated immune cells while sparing others and peripheral toxicity
2024 · Aurore Morello, Caroline Mary, et al. · Cancer Research
852 Modified-epitope-based vaccine (OSE2101) combined with anti-PD-1/IL-7v bispecific antibody sustains long-lasting tumor specific antigen memory T cell response in vivo
2023 · Belarif Lyssia, Julien Taurelle, et al. · Journal for ImmunoTherapy of Cancer
PDF
493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoralin vivoefficacies in humanized preclinical models
2023 · Irène Baccelli, Caroline Mary, et al. · Journal for ImmunoTherapy of Cancer
PDF
1369 Abstract withdrawn
2023 · Caroline Mary, Virginie Thepenier, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 6358: CLEC-1 inhibitory myeloid checkpoint blockade enhances antitumor responses and tumor phagocytosis by macrophages
2023 · Vanessa Gauttier, Irène Baccelli, et al. · Cancer Research
Abstract 6365: TRIM21 is a novel endogenous partner of the inhibitory myeloid checkpoint CLEC-1 involved in tumor antigen cross-presentation
2023 · Irene Baccelli, Vanessa Gauttier, et al. · Cancer Research
484 Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation
2022 · Vanessa Gauttier, Marion Drouin, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 12
Citation count: 22
H-index: 1
I10-index: 1
Year
Topic
Type